home / stock / autl / autl articles
In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMT Review of pooled analysis of the ongoing FELIX Phase Ib/II s...
LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-ge...
LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-ge...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...
Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024 Market Authorization Application (M...